Tag Archive for: compass

compass pathways psilocybin

Compass Pathways Phase 2 Psilocybin Results far from Spectacular

Psilocybin showed rapid antidepressant effects for most patients, but only 1 in 5 participants showed significant improvement at 12 weeks
psychedelic patent issues

Patent Controversies in Psychedelics

What investors need to know about the intellectual property behind medicine’s next big growth area
Math over Myth

Math Over Myth: These Psychedelic Stocks Made Confirmed Bottoms in Q3

Math over Myth is your weekly update on psychedelic stocks and ETFs, including ATAI, COMPASS, Cybin, GH Research, Mindset, Numinus, and more
Math over Myth

Math Over Myth: September Psychedelic Stock News Roundup

Track the monthly performance of the psychedelic stock sector with our Math over Myth Stock News Roundup
Math over Myth ATAI Compass

Math Over Myth: Spotlight on Psychedelic Stocks ATAI & COMPASS

If you want to invest in psychedelic stocks, ignore the hype and look at the technicals. We take a deep dive on atai Life Sciences & COMPASS Pathways
Compass Pathways Sued

Compass Pathways Sued for Stealing Trade Secrets

Compass Pathways faces a legal challenge from Terran Biosciences over the potential theft of intellectual property

The Battle for Psychedelic Patents

Psychedelic companies rely on novel patents to boost their value, but many players in the space are chasing the same IP
Psychedelic Business Spotlight – June 24

This Week in Psychedelic Stocks: Compass Pathways Wins Patent Battle, MindMed Patents Candy Flipping, and More!

, ,
This week in psychedelic stock news, there are big patent developments for Compass, MindMed and Numinus.
Compass Pathways Psilocybin Patent Upheld

Compass Pathways Psilocybin Patent Upheld

Compass Pathways scores a major victory in their bid to patent Comp 360, a proprietary formulation of psilocybin.